M. Michels

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

Jordan M. Graff, Michael B. Goldstein, Khoi D. Tran, 2022, The Lancet.

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

Susan Schneider, Mark Michels, J. P. Sy, 2006, The New England journal of medicine.

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.

Mark Michels, J. P. Sy, Peter K Kaiser, 2009, Ophthalmology.

METASTATIC BREAST CARCINOMA TO THE VITREOUS

H. Grossniklaus, M. Michels, W. Clark, 2004, Retina.

ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Peter K. Kaiser, Mark Michels, Gisèle Soubrane, 2006 .

TOWARD EARLIER DETECTION OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION: Multicenter Evaluation of a Preferential Hyperacuity Perimeter Designed as a Home Device

J. R. Ferencz, Y. Manor, D. Roth, 2010, Retina.